An Efficient Way to Determine HRQoL in Bronchiectasis Patients

Although health-related quality of life (HRQoL) is a crucial endpoint in bronchiectasis, it is difficult to determine because many HRQoL surveys are cumbersome or not bronchiectasis-validated. In this study multicenter prospective study, the use of the Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT), an easy-to-use survey, in bronchiectasis was evaluated. The following CAT psychometric properties were measured: internal consistency (Cronbach´s α), repeatability (test-retest, intra-class correlation coefficient [ICC]), discriminant validity (correlation with severity scores), convergent validity (correlation with validated QoL questionnaire, along with other variables), longitudinal validity (measured before and after each exacerbation during follow-up), predictive validity to future exacerbations, and minimum clinically important difference (MCID). Patients were followed up for one year. Final analysis included 96 bronchiectasis patients (mean age [SD] 62.2 [15.6] years; 79.2% were female). Internal consistency was excellent (α, 0.95), as was repeatability (ICC, 0.95). CAT validity was considered excellent in nearly all measures, the majority of which presented a Pearson coefficient > 0.40, with the only exception being in the correlations with the severity scores, which had a Pearson coefficient between 0.22 and 0.26. Sensitivity to change before and after exacerbations was established between 5.4 and 5.8 points. Patients with a CAT value of at least 10 points was predictive of patients with more than one exacerbation. The MCID was set at three points. Read more